Journal of Postgraduate Medicine, Education and Research

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  58 (2024)
Volume  57 (2023)
Volume  56 (2022)
Volume  55 (2021)
Volume  54 (2020)
Volume  53 (2019)
Volume  52 (2018)
Volume  51 (2017)
Volume  50 (2016)
Volume  49 (2015)
Volume  48 (2014)
Volume  47 (2013)
Volume  46 (2012)
Related articles

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

REVIEW ARTICLE

Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine

Richard P Baum, Harshad R Kulkarni

Citation Information : Baum RP, Kulkarni HR. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. J Postgrad Med Edu Res 2013; 47 (1):47-53.

DOI: 10.5005/jp-journals-10028-1055

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

How to cite this article

Kulkarni HR, Baum RP. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. J Postgrad Med Edu Res 2013; 47(1):47-53.

PDF Share
  1. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012;42:190-207.
  2. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33;652-58.
  3. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: On the way to theranostics. Dalton Trans 2011;40:6104-11.
  4. WAP A simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem 2012;23:1712-17.
  5. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyrc3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med Mol Imaging 1997;24: 368-71.
  6. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-18.
  7. [177Lu-DOTAOTyr3] octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
  8. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumours: Characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imag 2010;54:61-67.
  9. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011;52:1412-17.
  10. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med Mol Imag 1993;20:716-31.
  11. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumours: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41: 1114-19.
  12. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med Mol Imaging 2001;28:1751-57.
  13. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
  14. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;8:1659-68.
  15. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37:67-77.
  16. Standardized uptake values of 68Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumours. J Nucl Med 2010;51:353-59.
  17. Functional imaging of neuroendocrine tumours with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55.
  18. Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? Hell J Nucl Med 2009;12:102-05.
  19. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: First human study. Eur J Nucl Med Mol Imag 2010;37:834
  20. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J Pept Sci 2011;17:405-12.
  21. 68Galabeled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345-55.
  22. Exendin-4-based radiopharmaceuticals for glucagon like peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010;51:1059-67.
  23. 68Ga- and 111In-labeled DOTARGD peptides for imaging of alphav beta3 integrin expression. Eur J Nucl Med Mol Imaging 2008;35:1507-15.
  24. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 2011;52:1803-10.
  25. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogs. Eur J Nucl Med Mol Imaging 2010; 37:1386-96.
  26. Ventilation/perfusion scans using Ga-68 labeled tracers. World J Nucl Med 2011;10:26-59.
  27. A gallium-labeled DOTAalpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004; 45:116-23.
  28. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111Inor 68Ga-labeled affibody molecules. J Nucl Med 2010;51: 892-97.
  29. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumour-host interactions? Int J Cancer 1994;56:681-88.
  30. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
  31. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-23.
  32. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumour. World J Gastroenterol 2009;15:5867-70.
  33. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTANOC. Cancer Biother Radiopharm 2007;22:406-16.
  34. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 2011;105:313-20.
  35. Postelution processing of (44)Ti/ (44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010;68:1636-41.
  36. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46:83-91.
  37. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62-66.
  38. Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-The Bad Berka experience. Theranostics 2012;2:437-47
  39. First clinical experience using 177Lu-BPAMD for the treatment of skeletal metastases in prostate cancer (Abstract). Eur J Nucl Med Mol Imaging 2011;38:225
  40. Radiolabeled GRPR-antagonists: New promising tools in the diagnosis and therapy of GRPR positive tumours (Abstract). World J Nucl Med 2011;10:26-59.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.